Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression have?
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression has 292 citations in the OpenAlex counts ScholarIQ stores.
When was Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression published?
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression has 2020 year in the ScholarIQ index.
What is the open-access status of Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression?
Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression has bronze oa status in the ScholarIQ index.
What is the DOI of Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression?
The DOI for Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression is on the source record.
What is the PMID of Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression?
The PMID for Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression is on the source record.
What is the OpenAlex record for Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression?
The OpenAlex for Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression is on the source record.